EA202192318A1 - 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии - Google Patents

5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии

Info

Publication number
EA202192318A1
EA202192318A1 EA202192318A EA202192318A EA202192318A1 EA 202192318 A1 EA202192318 A1 EA 202192318A1 EA 202192318 A EA202192318 A EA 202192318A EA 202192318 A EA202192318 A EA 202192318A EA 202192318 A1 EA202192318 A1 EA 202192318A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
treatment
depression
dimethyltryptamine
dmt
Prior art date
Application number
EA202192318A
Other languages
English (en)
Inventor
Тайс Тервей
Original Assignee
Гх Рисерч Айрленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гх Рисерч Айрленд Лимитед filed Critical Гх Рисерч Айрленд Лимитед
Publication of EA202192318A1 publication Critical patent/EA202192318A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложены композиции для применения при лечении пациента, страдающего психическим расстройством, в частности клинической депрессией, трудноизлечимым депрессивным расстройством, тревожным расстройством, посттравматическим стрессовым расстройством, телесным дисморфическим расстройством, обсессивно-компульсивным расстройством, расстройством пищевого поведения и злоупотреблением психоактивными веществами. Кроме того, представлены схемы дозирования для лечения этих расстройств.
EA202192318A 2019-02-22 2020-02-24 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии EA202192318A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22
PCT/EP2020/054803 WO2020169850A1 (en) 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Publications (1)

Publication Number Publication Date
EA202192318A1 true EA202192318A1 (ru) 2021-12-21

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192318A EA202192318A1 (ru) 2019-02-22 2020-02-24 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии

Country Status (22)

Country Link
US (1) US20220071958A1 (ru)
EP (3) EP3927337B8 (ru)
JP (1) JP2022521337A (ru)
KR (1) KR20210154966A (ru)
CN (1) CN114555078A (ru)
AU (1) AU2020225410A1 (ru)
BR (1) BR112021016153A2 (ru)
CA (1) CA3130406A1 (ru)
CL (1) CL2021002174A1 (ru)
CO (1) CO2021010882A2 (ru)
CR (1) CR20210437A (ru)
DK (1) DK3927337T3 (ru)
DO (1) DOP2021000176A (ru)
EA (1) EA202192318A1 (ru)
EC (1) ECSP21060868A (ru)
FI (1) FI3927337T3 (ru)
IL (1) IL285537A (ru)
MA (1) MA55021A (ru)
MX (1) MX2021009941A (ru)
NI (1) NI202100080A (ru)
PE (1) PE20220015A1 (ru)
WO (1) WO2020169850A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
WO2021089872A1 (en) 2019-11-07 2021-05-14 Small Pharma Ltd Compounds
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
JP2023530292A (ja) 2020-06-12 2023-07-14 ベックリー・サイテック・リミテッド ５－メトキシ－ｎ，ｎ－ジメチルトリプタミンの安息香酸塩を含む組成物
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
WO2022069690A2 (en) * 2020-10-02 2022-04-07 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
WO2022117640A1 (en) * 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
BR112023022195A2 (pt) 2021-04-26 2024-01-16 Atai Therapeutics Inc Novas composições e métodos de n,n-dimetiltriptamina
WO2022235927A1 (en) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Novel tryptamines and methods of treating mood disorders
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023089132A1 (en) * 2021-11-18 2023-05-25 Small Pharma Ltd Injectable and inhalable formulations
WO2023186798A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited 5-meo-dmt for use in the treatment of sleep disturbance
WO2023186829A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment
FI4313945T3 (fi) 2022-03-27 2024-05-23 Gh Res Ireland Limited 5-meo-dmt:n kiteinen hydrobromidisuola
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1625336B9 (en) 2003-05-21 2012-03-21 Alexza Pharmaceuticals, Inc. Use of a layer of solid fuel, method for producing such a layer and associated heating unit
EP1884254B8 (de) 2006-08-01 2011-02-23 Stobi GmbH & Co. KG Ventilballon für Inhalatoren
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
WO2018195455A1 (en) * 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques

Also Published As

Publication number Publication date
KR20210154966A (ko) 2021-12-21
EP3927337B1 (en) 2024-02-14
MA55021A (fr) 2021-12-29
DK3927337T3 (da) 2024-04-22
EP4349407A2 (en) 2024-04-10
JP2022521337A (ja) 2022-04-06
CN114555078A (zh) 2022-05-27
NI202100080A (es) 2021-12-06
MX2021009941A (es) 2021-12-10
CL2021002174A1 (es) 2022-01-28
WO2020169850A1 (en) 2020-08-27
CR20210437A (es) 2021-11-02
BR112021016153A2 (pt) 2021-10-05
DOP2021000176A (es) 2021-11-21
CA3130406A1 (en) 2020-08-27
FI3927337T3 (fi) 2024-05-08
PE20220015A1 (es) 2022-01-11
AU2020225410A1 (en) 2021-08-19
EP4353314A2 (en) 2024-04-17
CO2021010882A2 (es) 2022-01-17
EP3927337B8 (en) 2024-03-20
ECSP21060868A (es) 2021-11-30
US20220071958A1 (en) 2022-03-10
IL285537A (en) 2021-09-30
EP3927337A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
EA202192318A1 (ru) 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии
EA202192319A1 (ru) Композиции, содержащие 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для применения в лечении психических расстройств
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112017014088A2 (pt) aparelho dentário que fornece superfícies oclusais expostas
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201300213A1 (ru) Применение ингибиторов dpp iv
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EA202192153A1 (ru) Ингибиторы для терапевтического применения
EA202190660A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
McDonell Persistent irritability: case report
Bergman Vomiting, stomach aches and giddiness: case report
Buggenhout Mirtazapine/olanzapine
Power Back and muscle pain: case report
Torr Fluvoxamine/mirtazapine/sertraline
Aljohani Inclusion body myositis: case report
EA202191927A1 (ru) Модуляторы gpr35
Tuten et al. The role of significant others and family members in substance abuse treatment.